Neuromuscular junctions as key contributors and therapeutic targets in spinal muscular atrophy

Frontiers in Neuroanatomy

Volumn 10, Issue FEB, 2016, Pages

  Boido, Marina ^a   Vercelli, Alessandro ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Denervation; Endplate; Immaturity; Motor neuron disease; Neurofilament; Therapy

Indexed keywords

AGRIN; ANTISENSE OLIGONUCLEOTIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLINERGIC RECEPTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LAMININ; MICRORNA; NEU DIFFERENTIATION FACTOR; NEUROTROPHIN 3; SOMATOMEDIN C; SURVIVAL MOTOR NEURON PROTEIN;

DISEASE COURSE; EXERCISE; GENE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; MOTOR PERFORMANCE; MUSCLE DENERVATION; MUSCLE INNERVATION; MUSCLE REINNERVATION; NERVE ENDING; NERVE STIMULATION; NEUROFILAMENT; NEUROMUSCULAR SYNAPSE; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PHYSICAL ACTIVITY; PROTEIN EXPRESSION; REVIEW; SPINAL MUSCULAR ATROPHY; SURVIVAL MOTOR NEURON GENE; SYNAPTIC TRANSMISSION;

EID: 84959018698     PISSN: None     EISSN: 16625129     Source Type: Journal    
DOI: 10.3389/fnana.2016.00006     Document Type: Review

References (87)

1. Arnold, A. S., Gueye, M., Guettier-Sigrist, S., Courdier-Fruh, I., Coupin, G., Poindron, P., et al. (2004). Reduced expression of nicotinic AChRs in myotubes from spinal muscular atrophy I patients. Lab. Invest. 84, 1271–1278. doi: 10.1038/labinvest.3700163.
2. Bennett, R. L., and Knowlton, G. C. (1958). Overwork weakness in partially denervated skeletal muscle. Clin. Orthop. 12, 22–29.
3. Bloch-Gallego, E. (2015). Mechanisms controlling neuromuscular junction stability. Cell. Mol. Life Sci. 72, 1029–1043. doi: 10.1007/s00018-014-1768-z.
4. Bogdanik, L. P., Osborne, M. A., Davis, C., Martin, W. P., Austin, A., Rigo, F., et al. (2015). Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II/III spinal muscular atrophy. Proc. Natl. Acad. Sci. U S A 112, E5863–E5872. doi: 10.1073/pnas.1509758112.
5. Bottai, D., and Adami, R. (2013). Spinal muscular atrophy: new findings for an old pathology. Brain Pathol. 23, 613–622. doi: 10.1111/bpa.12071.
6. Bowerman, M., Anderson, C. L., Beauvais, A., Boyl, P. P., Witke, W., and Kothary, R. (2009). SMN, profilin IIa and plastin 3: a link between the deregulation of actin dynamics and SMA pathogenesis. Mol. Cell. Neurosci. 42, 66–74. doi: 10.1016/j.mcn.2009.05.009.
7. Bowerman, M., Shafey, D., and Kothary, R. (2007). Smn depletion alters profilin II expression and leads to upregulation of the RhoA/ROCK pathway and defects in neuronal integrity. J. Mol. Neurosci. 32, 120–131. doi: 10.1007/s12031-007-0024-5.
8. Bruneteau, G., Simonet, T., Bauché, S., Mandjee, N., Malfatti, E., Girard, E., et al. (2013). Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression. Brain 136, 2359–2368. doi: 10.1093/brain/awt164.
9. Buffelli, M., Busetto, G., Bidoia, C., Favero, M., and Cangiano, A. (2004). Activity-dependent synaptic competition at mammalian neuromuscular junctions. News Physiol. Sci. 19, 85–91. doi: 10.1152/nips.01464.2003.
10. Burghes, A. H., and Beattie, C. E. (2009). Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat. Rev. Neurosci. 10, 597–609. doi: 10.1038/nrn2670.
11. Caygill, E. E., and Johnston, L. A. (2008). Temporal regulation of metamorphic processes in Drosophila by the let-7 and miR-125 heterochronic microRNAs. Curr. Biol. 18, 943–950. doi: 10.1016/j.cub.2008.06.020.
12. Cifuentes-Diaz, C., Nicole, S., Velasco, M. E., Borra-Cebrian, C., Panozzo, C., Frugier, T., et al. (2002). Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model. Hum. Mol. Genet. 11, 1439–1447. doi: 10.1093/hmg/11.12.1439.
13. Comley, L. H., Nijssen, J., Frost-Nylen, J., and Hedlund, E. (2015). Cross disease comparison of amyotrophic lateral sclerosis and spinal muscular atrophy reveals conservation of selective vulnerability but differential neuromuscular junction pathology. J. Comp. Neurol. doi: 10.1002/cne.23917 [Epub ahead of print].
14. Corti, S., Nizzardo, M., Nardini, M., Donadoni, C., Salani, S., Del Bo, R., et al. (2009). Motoneuron transplantation rescues the phenotype of SMARD1 (spinal muscular atrophy with respiratory distress type 1). J. Neurosci. 29, 11761–11771. doi: 10.1523/JNEUROSCI.2734-09.2009.
15. Dale, J. M., Shen, H., Barry, D. M., Garcia, V. B., Rose, F. F., Jr., Lorson, C. L., et al. (2011). The spinal muscular atrophy mouse model, SMAΔ7, displays altered axonal transport without global neurofilament alterations. Acta Neuropathol. 122, 331–341. doi: 10.1007/s00401-011-0848-5.
16. D’Amico, A., Mercuri, E., Tiziano, F. D., and Bertini, E. (2011). Spinal muscular atrophy. Orphanet J. Rare Dis. 6:71. doi: 10.1186/1750-1172-6-71.
17. DeChiara, T. M., Bowen, D. C., Valenzuela, D. M., Simmons, M. V., Poueymirou, W. T., Thomas, S., et al. (1996). The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 85, 501–512. doi: 10.1016/s0092-8674(00)81251-9.
18. d’Errico, P., Boido, M., Piras, A., Valsecchi, V., De Amicis, E., Locatelli, D., et al. (2013). Selective vulnerability of spinal and cortical motor neuron subpopulations in delta7 SMA mice. PLoS One 8:e82654. doi: 10.1371/journal.pone.0082654.
19. Dombert, B., Sivadasan, R., Simon, C. M., Jablonka, S., and Sendtner, M. (2014). Presynaptic localization of SMN and hnRNP R in axon terminals of embryonic and postnatal mouse motoneurons. PLoS One 9:e110846. doi: 10.1371/journal.pone.0110846.
20. Fallini, C., Bassell, G. J., and Rossoll, W. (2012). Spinal muscular atrophy: the role of SMN in axonal mRNA regulation. Brain Res. 1462, 81–92. doi: 10.1016/j.brainres.2012.01.044.
21. Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., and Wirth, B. (2002). Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am. J. Hum. Genet. 70, 358–368. doi: 10.1086/338627.
22. Ferraiuolo, L., De Bono, J. P., Heath, P. R., Holden, H., Kasher, P., Channon, K. M., et al. (2009). Transcriptional response of the neuromuscular system to exercise training and potential implications for ALS. J. Neurochem. 109, 1714–1724. doi: 10.1111/j.1471-4159.2009.06080.x.
23. Gautam, M., Noakes, P. G., Moscoso, L., Rupp, F., Scheller, R. H., Merlie, J. P., et al. (1996). Defective neuromuscular synaptogenesis in agrin-deficient mutant mice. Cell 85, 525–535. doi: 10.1016/s0092-8674(00)81253-2.
24. Grondard, C., Biondi, O., Armand, A. S., Lécolle, S., Della Gaspera, B., Pariset, C., et al. (2005). Regular exercise prolongs survival in a type 2 spinal muscular atrophy model mouse. J. Neurosci. 25, 7615–7622. doi: 10.1523/jneurosci.1245-05.2005.
25. Haase, G., Kennel, P., Pettmann, B., Vigne, E., Akli, S., Revah, F., et al. (1997). Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nat. Med. 3, 429–436. doi: 10.1038/nm0497-429.
26. Haramati, S., Chapnik, E., Sztainberg, Y., Eilam, R., Zwang, R., Gershoni, N., et al. (2010). miRNA malfunction causes spinal motor neuron disease. Proc. Natl. Acad. Sci. U S A 107, 13111–13116. doi: 10.1073/pnas.1006151107.
27. Harding, B. N., Kariya, S., Monani, U. R., Chung, W. K., Benton, M., Yum, S. W., et al. (2015). Spectrum of neuropathophysiology in spinal muscular atrophy type I. J. Neuropathol. Exp. Neurol. 74, 15–24. doi: 10.1097/NEN.0000000000000144.
28. Hettwer, S., Lin, S., Kucsera, S., Haubitz, M., Oliveri, F., Fariello, R. G., et al. (2014). Injection of a soluble fragment of neural agrin (NT-1654) considerably improves the muscle pathology caused by the disassembly of the neuromuscular junction. PLoS One 9:e88739. doi: 10.1371/journal.pone.0088739.
29. Jiang, J., Yao, P., Gu, Y., Xu, L., Xu, J., and Tan, H. (2012). Adult rat mesenchymal stem cells delay denervated muscle atrophy. Cell. Mol. Neurobiol. 32, 1287–1298. doi: 10.1007/s10571-012-9853-z.
30. Kariya, S., Obis, T., Garone, C., Akay, T., Sera, F., Iwata, S., et al. (2014). Requirement of enhanced survival motoneuron protein imposed during neuromuscular junction maturation. J. Clin. Invest. 124, 785–800. doi: 10.1172/JCI72017.
31. Kariya, S., Park, G. H., Maeno-Hikichi, Y., Leykekhman, O., Lutz, C., Arkovitz, M. S., et al. (2008). Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 17, 2552–2569. doi: 10.1093/hmg/ddn156.
32. Keil, J. M., Seo, J., Howell, M. D., Hsu, W. H., Singh, R. N., and DiDonato, C. J. (2014). A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy. Mol. Ther. Nucleic Acids 3:e174. doi: 10.1038/mtna.2014.23.
33. Kim, N., Stiegler, A. L., Cameron, T. O., Hallock, P. T., Gomez, A. M., Huang, J. H., et al. (2008). Lrp4 is a receptor for agrin and forms a complex with MuSK. Cell 135, 334–342. doi: 10.1016/j.cell.2008.10.002.
34. Kong, L., Wang, X., Choe, D. W., Polley, M., Burnett, B. G., Bosch-Marcé, M., et al. (2009). Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J. Neurosci. 29, 842–851. doi: 10.1523/JNEUROSCI.4434-08.2009.
35. Kreutzer, M., Seehusen, F., Kreutzer, R., Pringproa, K., Kummerfeld, M., Claus, P., et al. (2012). Axonopathy is associated with complex axonal transport defects in a model of multiple sclerosis. Brain Pathol. 22, 454–471. doi: 10.1111/j.1750-3639.2011.00541.x.
36. Kues, W. A., Brenner, H. R., Sakmann, B., and Witzemann, V. (1995). Local neurotrophic repression of gene transcripts encoding fetal AChRs at rat neuromuscular synapses. J. Cell Biol. 130, 949–957. doi: 10.1083/jcb.130.4.949.
37. Kye, M. J., and Gonçalves Ido, C. (2014). The role of miRNA in motor neuron disease. Front. Cell. Neurosci. 8:15. doi: 10.3389/fncel.2014.00015.
38. Lee, A. J., Awano, T., Park, G. H., and Monani, U. R. (2012). Limited phenotypic effects of selectively augmenting the SMN protein in the neurons of a mouse model of severe spinal muscular atrophy. PLoS One 7:e46353. doi: 10.1371/journal.pone.0046353.
39. Lee, Y. I., Mikesh, M., Smith, I., Rimer, M., and Thompson, W. (2011). Muscles in a mouse model of spinal muscular atrophy show profound defects in neuromuscular development even in the absence of failure in neuromuscular transmission or loss of motor neurons. Dev. Biol. 356, 432–444. doi: 10.1016/j.ydbio.2011.05.667.
40. Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., et al. (1995). Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155–165. doi: 10.1016/0092-8674(95)90460-3.
41. Li, D. K., Tisdale, S., Lotti, F., and Pellizzoni, L. (2014). SMN control of RNP assembly: from post-transcriptional gene regulation to motor neuron disease. Semin. Cell Dev. Biol. 32, 22–29. doi: 10.1016/j.semcdb.2014.04.026.
42. Ling, K. K., Gibbs, R. M., Feng, Z., and Ko, C. P. (2012). Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy. Hum. Mol. Genet. 21, 185–195. doi: 10.1093/hmg/ddr453.
43. Liu, H., Beauvais, A., Baker, A. N., Tsilfidis, C., and Kothary, R. (2011). Smn deficiency causes neuritogenesis and neurogenesis defects in the retinal neurons of a mouse model of spinal muscular atrophy. Dev. Neurobiol. 2011, 153–169. doi: 10.1002/dneu.20840.
44. Liu, N., Williams, A. H., Maxeiner, J. M., Bezprozvannaya, S., Shelton, J. M., Richardson, J. A., et al. (2012). microRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice. J. Clin. Invest. 122, 2054–2065. doi: 10.1172/JCI62656.
45. Lorson, C. L., Hahnen, E., Androphy, E. J., and Wirth, B. (1999). A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. U S A 96, 6307–6311. doi: 10.1073/pnas.96.11.6307.
46. Luchetti, A., Ciafrè, S. A., Murdocca, M., Malgieri, A., Masotti, A., Sanchez, M., et al. (2015). A perturbed MicroRNA expression pattern characterizes embryonic neural stem cells derived from a severe mouse model of Spinal Muscular Atrophy (SMA). Int. J. Mol. Sci. 16, 18312–18327. doi: 10.3390/ijms160818312.
47. Macintosh, B., Gardiner, P., and McComas, A. (2006). Skeletal Muscle: Form and Function, 2nd Edn. Champaign, IL: Human Kinetics.
48. Marques, M. J., Conchello, J. A., and Lichtman, J. W. (2000). From plaque to pretzel: fold formation and acetylcholine receptor loss at the developing neuromuscular junction. J. Neurosci. 20, 3663–3675.
49. Martinez, T. L., Kong, L., Wang, X., Osborne, M. A., Crowder, M. E., Van Meerbeke, J. P., et al. (2012). Survival motor neuron protein in motor neurons determines synaptic integrity in spinal muscular atrophy. J. Neurosci. 32, 8703–8715. doi: 10.1523/JNEUROSCI.0204-12.2012.
50. Mazzini, L., Vercelli, A., Ferrero, I., Mareschi, K., Boido, M., Servo, S., et al. (2009). Stem cells in amyotrophic lateral sclerosis: state of the art. Expert Opin. Biol. Ther. 9, 1245–1258. doi: 10.1517/14712590903186956.
51. McGovern, V. L., Gavrilina, T. O., Beattie, C. E., and Burghes, A. H. (2008). Embryonic motor axon development in the severe SMA mouse. Hum. Mol. Genet. 17, 2900–2909. doi: 10.1093/hmg/ddn189.
52. McMahan, U. J. (1990). The agrin hypothesis. Cold Spring Harb. Symp. Quant. Biol. 55, 407–418. doi: 10.1101/sqb.1990.055.01.041.
53. Missias, A. C., Chu, G. C., Klocke, B. J., Sanes, J. R., and Merlie, J. P. (1996). Maturation of the acetylcholine receptor in skeletal muscle: regulation of the AChR gamma-to-epsilon switch. Dev. Biol. 179, 223–238. doi: 10.1006/dbio.1996.0253.
54. Murray, L. M., Comley, L. H., Thomson, D., Parkinson, N., Talbot, K., and Gillingwater, T. H. (2008). Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 17, 949–962. doi: 10.1093/hmg/ddm367.
55. Nishimune, H., Stanford, J. A., and Mori, Y. (2014). Role of exercise in maintaining the integrity of the neuromuscular junction. Muscle Nerve 49, 315–324. doi: 10.1002/mus.24095.
56. Paez-Colasante, X., Seaberg, B., Martinez, T. L., Kong, L., Sumner, C. J., and Rimer, M. (2013). Improvement of neuromuscular synaptic phenotypes without enhanced survival and motor function in severe spinal muscular atrophy mice selectively rescued in motor neurons. PLoS One 8:e75866. doi: 10.1371/journal.pone.0075866.
57. Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., et al. (2011). Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 3:72ra18. doi: 10.1126/scitranslmed.3001777.
58. Porensky, P. N., and Burghes, A. H. (2013). Antisense oligonucleotides for the treatment of spinal muscular atrophy. Hum. Gene Ther. 24, 489–498. doi: 10.1089/hum.2012.225.
59. Prior, T. W., Snyder, P. J., Rink, B. D., Pearl, D. K., Pyatt, R. E., Mihl, D. C., et al. (2010). Newborn and carrier screening for spinal muscular atrophy. Am. J. Med. Genet. A 152A, 1608–1616. doi: 10.1002/ajmg.a.33474.
60. Reist, N. E., Werle, M. J., and McMahan, U. J. (1992). Agrin released by motor neurons induces the aggregation of acetylcholine receptors at neuromuscular junctions. Neuron 8, 865–868. doi: 10.1016/0896-6273(92)90200-w.
61. Robbins, K. L., Glascock, J. J., Osman, E. Y., Miller, M. R., and Lorson, C. L. (2014). Defining the therapeutic window in a severe animal model of spinal muscular atrophy. Hum. Mol. Genet. 23, 4559–4568. doi: 10.1093/hmg/ddu169.
62. Ruegg, M. A., Tsim, K. W., Horton, S. E., Kröger, S., Escher, G., Gensch, E. M., et al. (1992). The agrin gene codes for a family of basal lamina proteins that differ in function and distribution. Neuron 8, 691–699. doi: 10.1016/0896-6273(92)90090-z.
63. Ruiz, R., Casañas, J. J., Torres-Benito, L., Cano, R., and Tabares, L. (2010). Altered intracellular Ca2+ homeostasis in nerve terminals of severe spinal muscular atrophy mice. J. Neurosci. 30, 849–857. doi: 10.1523/JNEUROSCI.4496-09.2010.
64. Slater, C. R. (1982). Postnatal maturation of nerve-muscle junctions in hindlimb muscles of the mouse. Dev. Biol. 94, 11–22. doi: 10.1016/0012-1606(82)90063-x.
65. Tintignac, L. A., Brenner, H. R., and Rüegg, M. A. (2015). Mechanisms regulating neuromuscular junction development and function and causes of muscle wasting. Physiol. Rev. 95, 809–852. doi: 10.1152/physrev.00033.2014.
66. Torres-Benito, L., Ruiz, R., and Tabares, L. (2012). Synaptic defects in spinal muscular atrophy animal models. Dev. Neurobiol. 72, 126–133. doi: 10.1002/dneu.20912.
67. Tsai, L. K. (2012). Therapy development for spinal muscular atrophy in SMN independent targets. Neural Plast. 2012:456478. doi: 10.1155/2012/456478.
68. Tsai, L. K., Chen, Y. C., Cheng, W. C., Ting, C. H., Dodge, J. C., Hwu, W. L., et al. (2012). IGF-1 delivery to CNS attenuates motor neuron cell death but does not improve motor function in type III SMA mice. Neurobiol. Dis. 45, 272–279. doi: 10.1016/j.nbd.2011.06.021.
69. Tsai, L. K., Tsai, M. S., Ting, C. H., and Li, H. (2008). Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J. Mol. Med. 86, 1243–1254. doi: 10.1007/s00109-008-0388-1.
70. Valdez, G., Heyer, M. P., Feng, G., and Sanes, J. R. (2014). The role of muscle microRNAs in repairing the neuromuscular junction. PLoS One 24:e93140. doi: 10.1371/journal.pone.0093140.
71. Valdez, G., Tapia, J. C., Kang, H., Clemenson, G. D., Jr., Gage, F. H., Lichtman, J. W., et al. (2010). Attenuation of age-related changes in mouse neuromuscular synapses by caloric restriction and exercise. Proc. Natl. Acad. Sci. U S A 107, 14863–14868. doi: 10.1073/pnas.1002220107.
72. Valsecchi, V., Boido, M., De Amicis, E., Piras, A., and Vercelli, A. (2015). Expression of muscle-specific MiRNA 206 in the progression of disease in a murine SMA model. PLoS One 10:e0128560. doi: 10.1371/journal.pone.0128560.
73. van Rooij, E., Liu, N., and Olson, E. N. (2008). MicroRNAs flex their muscles. Trends Genet. 24, 159–166. doi: 10.1016/j.tig.2008.01.007.
74. Villanova, M., and Bach, J. R. (2015). Allogeneic mesenchymal stem cell therapy outcomes for three patients with spinal muscular atrophy type 1. Am. J. Phys. Med. Rehabil. 94, 410–415. doi: 10.1097/PHM.0000000000000309.
75. Vock, V. M., Ponomareva, O. N., and Rimer, M. (2008). Evidence for muscle-dependent neuromuscular synaptic site determination in mammals. J. Neurosci. 28, 3123–3130. doi: 10.1523/JNEUROSCI.5080-07.2008.
76. Wadman, R. I., Vrancken, A. F., van den Berg, L. H., and van der Pol, W. L. (2012). Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology 79, 2050–2055. doi: 10.1212/WNL.0b013e3182749eca.
77. Walsh, M. K., and Lichtman, J. W. (2003). In vivo time-lapse imaging of synaptic takeover associated with naturally occurring synapse elimination. Neuron 37, 67–73. doi: 10.1016/s0896-6273(02)01142-x.
78. Wang, L. T., Chiou, S. S., Liao, Y. M., Jong, Y. J., and Hsu, S. H. (2014). Survival of motor neuron protein downregulates miR-9 expression in patients with spinal muscular atrophy. Kaohsiung J. Med. Sci. 30, 229–234. doi: 10.1016/j.kjms.2013.12.007.
79. Wang, T., Xie, K., and Lu, B. (1995). Neurotrophins promote maturation of developing neuromuscular synapses. J. Neurosci. 15, 4796–4805.
80. Williams, A. H., Valdez, G., Moresi, V., Qi, X., McAnally, J., Elliott, J. L., et al. (2009). MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 326, 1549–1554. doi: 10.1126/science.1181046.
81. Witzemann, V. (2006). Development of the neuromuscular junction. Cell Tissue Res. 326, 263–271. doi: 10.1007/s00441-006-0237-x.
82. Wu, H., Xiong, W. C., and Mei, L. (2010). To build a synapse: signaling pathways in neuromuscular junction assembly. Development 137, 1017–1033. doi: 10.1242/dev.038711.
83. Wyatt, T. J., and Keirstead, H. S. (2010). Stem cell-derived neurotrophic support for the neuromuscular junction in spinal muscular atrophy. Expert Opin. Biol. Ther. 10, 1587–1594. doi: 10.1517/14712598.2010.529895.
84. Yoshida, M., Kitaoka, S., Egawa, N., Yamane, M., Ikeda, R., Tsukita, K., et al. (2015). Modeling the early phenotype at the neuromuscular junction of spinal muscular atrophy using patient-derived iPSCs. Stem Cell Reports 4, 561–568. doi: 10.1016/j.stemcr.2015.02.010.
85. Zhang, Z., Pinto, A. M., Wan, L., Wang, W., Berg, M. G., Oliva, I., et al. (2013). Dysregulation of synaptogenesis genes antecedes motor neuron pathology in spinal muscular atrophy. Proc. Natl. Acad. Sci. U S A 110, 19348–19353. doi: 10.1073/pnas.1319280110.
86. Zhang, B. G., Quigley, A. F., Bourke, J. L., Nowell, C. J., Myers, D. E., Choong, P. F., et al. (2015). Combination of agrin and laminin increase acetylcholine receptor clustering and enhance functional neuromuscular junction formation In vitro. Dev. Neurobiol. doi: 10.1002/dneu.22331 [Epub ahead of print].
87. Zhu, H., Bhattacharyya, B. J., Lin, H., and Gomez, C. M. (2013). Skeletal muscle calpain acts through nitric oxide and neural miRNAs to regulate acetylcholine release in motor nerve terminals. J. Neurosci. 33, 7308–7324. doi: 10.1523/JNEUROSCI.0224-13.2013.